A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

Study Identifier
M26-116
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Healthy Volunteer
  • Study Drug
  • ABBV-1451
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 60 Years

    Protocol Summary

    The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.

    Study Locations

    Location
    Status
    Location
    Acpru /Id# 282128
    Grayslake, Illinois, United States, 60030
    Status
    Recruiting